Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.08
-12.8%
$5.06
$3.42
$7.20
$229.35M1.821.56 million shs4.79 million shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$21.30
-1.3%
$18.88
$13.30
$30.03
$1.05B0.79291,067 shs518,501 shs
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
$13.48
-1.8%
$14.84
$8.24
$18.38
$878.56M-0.17530,943 shs2.90 million shs
Pharvaris N.V. stock logo
PHVS
Pharvaris
$17.99
+8.1%
$16.42
$11.51
$25.50
$940.70M-2.8671,894 shs62,025 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.00%-30.26%-25.68%-8.52%-28.67%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
0.00%-2.78%+27.01%+1.04%+4.05%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
0.00%-5.87%-17.40%-20.09%+14.33%
Pharvaris N.V. stock logo
PHVS
Pharvaris
0.00%+7.72%+9.76%+16.82%-6.88%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.23 of 5 stars
0.02.00.00.01.00.80.6
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.6519 of 5 stars
3.51.00.00.03.14.20.0
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2.8016 of 5 stars
3.43.00.00.02.04.20.0
Pharvaris N.V. stock logo
PHVS
Pharvaris
1.369 of 5 stars
3.51.00.00.01.90.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.00
Buy$39.6085.92% Upside
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2.75
Moderate Buy$32.25139.24% Upside
Pharvaris N.V. stock logo
PHVS
Pharvaris
3.00
Buy$36.20101.22% Upside

Current Analyst Ratings Breakdown

Latest ACB, MLYS, ELVN, and PHVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00
6/16/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.00
6/16/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$37.00
6/11/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$32.00
6/10/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$15.00
6/5/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$27.00
5/16/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$36.00 ➝ $27.00
5/15/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$39.00 ➝ $40.00
5/14/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$48.00
5/14/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$28.00 ➝ $25.00
5/13/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$200.35M1.14$0.22 per share18.26$8.18 per share0.50
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$6.34 per shareN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/A$3.84 per shareN/A
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/A$5.54 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.0537.099.27N/A1.32%0.13%0.10%8/6/2025 (Estimated)
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$89.02M-$1.92N/AN/AN/AN/A-31.84%-30.09%8/12/2025 (Estimated)
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$177.81M-$3.73N/AN/AN/AN/A-71.15%-65.71%8/12/2025 (Estimated)
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$145.24M-$3.01N/AN/AN/AN/A-54.02%-50.36%8/13/2025 (Estimated)

Latest ACB, MLYS, ELVN, and PHVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
5/14/2025Q1 2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.51-$0.57-$0.06-$0.57N/AN/A
5/13/2025Q1 2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$0.80-$0.89-$0.09-$0.89N/AN/A
5/12/2025Q1 2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$1.02-$0.79+$0.23-$0.79N/AN/A
4/7/2025Q4 2024
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$0.74-$0.68+$0.06-$0.68N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/AN/A
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
21.07
21.06
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/A
26.48
26.48
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A
11.10
11.10

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
84.46%
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
25.90%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
25.56%
Pharvaris N.V. stock logo
PHVS
Pharvaris
11.84%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,07356.21 million56.21 millionOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5049.07 million36.36 millionOptionable
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2865.18 million48.52 millionOptionable
Pharvaris N.V. stock logo
PHVS
Pharvaris
3052.29 million46.10 millionNot Optionable

Recent News About These Companies

Brokerages Set Pharvaris (NASDAQ:PHVS) Price Target at $36.20
Pharvaris Announces Annual Meeting of Shareholders

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.08 -0.60 (-12.82%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$4.10 +0.01 (+0.37%)
As of 06/20/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$21.30 -0.27 (-1.25%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$21.30 0.00 (0.00%)
As of 06/20/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Mineralys Therapeutics stock logo

Mineralys Therapeutics NASDAQ:MLYS

$13.48 -0.25 (-1.82%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$13.48 -0.01 (-0.04%)
As of 06/20/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Pharvaris stock logo

Pharvaris NASDAQ:PHVS

$17.99 +1.35 (+8.11%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$17.89 -0.10 (-0.58%)
As of 06/20/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.